The International Generic Drug Regulators Pilot (IGDRP) was launched in April 2012 in the face of mounting pressures that confront generic drug review programs worldwide and a willingness on the part of regulatory agencies to pursue collaboration and convergence to help mitigate these pressures.
The IGDRP operated for a three-year period on interim operating procedures for the Pilot. The seventh and final meeting of the International Generic Drug Regulators Pilot took place in Singapore, November 2 to 5, 2014.
The IGDRP Steering Committee recognized the considerable progress made by the Pilot and recommended extending the initiative for a further two years, from January 2015 to December 2016 and to change the initiative's name to 'International Generic Drug Regulators Program'.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze